Connect with us

Featured

And The Award Goes To Netflix

Daniel Chase

Published

on

stock_price_netflix

Many moons ago, the world gifted us with something we’d eventually realize that life before this object was without purpose. Some call it a waste of time, while others refer to this experience as something akin to dying, visiting heaven, and coming back, but we’ll just call it by its name: media streaming. Utilizing the god-like energy of the internet, mere humans can stream any and all content that they could possibly imagine.

As of a few years ago, Netflix (NFLX), perhaps the king of all streaming sites, offered its users more than 100 million hours of streamable programming. To put those numbers into perspective, if you wanted to watch every show, movie, and documentary on Netflix (NFLX), it would take you three years, two-hundred days, twelve hours, and fourteen minutes to do so, and that’s if you watched without stopping. In other words, Netflix (NFLX) has plenty to watch. 

What began as a means of adding a new, innovative way for people to view their favorite movies and TV shows has since become a brand associated with releasing films and shows that have beaten out studio content during award season.

Since Netflix (NFLX) began releasing original content back in 2013, the streaming-giant-turned-production-company has won thirty-seven Emmy awards, four Golden Globes, and two Academy Awards. While I 100% agree that Netflix (NFLX) content has earned every single award that they’ve won, these victories are an indication that old Hollywood is fading softly into the distance. 

Last year, box office films earned nearly $12 billion, representing the highest in history, but, as several analysts have pointed it, that was largely due to the recent increase in ticket prices. In fact, according to TechCrunch, the total number of movie tickets sold in America has dropped over 10% in the last two decades even though domestic population levels continue to rise. The reason behind this must be that moviegoers would rather watch award-winning content for $10/month, from the comfort of their own living room, rather than pay $15 per movie and possibly have to sit among crying babies and loud fans of The Avengers. 

“This cash loss exists because Netflix is funding next year’s content against this year’s revenue. Netflix could have chosen to stabilize its 2018 content offering at 2017 levels…The industry and press would do well to focus on Netflix’s cash spend — even when compared to the recognized spend of its traditional peers. Netflix’s amortization figure is a lagging indictor. What’s scary is what’s going out the door: lots and lots of cash.”

Matthew Ball, former Head of Strategy, Amazon Studios 

In recognition of the potential dethroning of tv/film studies, companies like Disney (DIS) have made moves to tap into the streaming business. Disney has said that it will have three major streaming services this year including Hulu, ESPN+, and a Disney-branded service launching later this year. 

Inside the secret boardroom located in Cinderella’s castle at Disney World, Bob Iger, Disney’s (DIS) CEO has been plotting, oh boy, is he plotting. Iger, the wonderful leader of Disney (DIS) announced in 2018  the name for its new streaming service set to launch this year: Disney+ (DIS). Iger also mentioned Disney+ will retain the rights to content from the many brands in the company’s pocket including Marvel, Star Wars, Pixar, ESPN, and National Geographic. 

Netflix (NFLX) has singlehandedly reshaped the tv/film industry as we’ve all come to know it. While Netflix (NFLX) presently cannot compete with the likes of Disney (DIS) and its multi-billion dollar Marvel Cinematic Universe, the streaming giant is proving that Hollywood can no longer sit calmly on the throne and assume dissension isn’t brewing in the kingdom. When asked about Netflix’s (NFLX) war on the traditional cinematic experience, the Company’s CEO, Reed Hastings, quipped that the movie business’s only innovation in the last 30 years has been that “the popcorn tastes better, but that’s about it.”

Continue Reading
Click to comment

Featured

Alibaba (BABA) Stock Price Signaling Buy Or Sell After The Recent Surge?

Joe Samuel

Published

on

technology stock price

China has grown into the world’s second-largest economy over the past few decades. One Chinese company that mirrors the remarkable growth of the country is Alibaba Group Holding Ltd – ADR (NYSE:BABA). The e-commerce behemoth is rightly called the ‘Amazon of China’ and it has grown at a remarkable pace over the past two decades.

Key Details

However, Jack Ma, who oversaw the company’s rise has decided to depart. Most analysts believe that Alibaba stock is still a buy despite this development. There are several factors to consider, however.

Jack Ma may have departed but the robust business model that he has created is still in place. That will likely continue to help drive the company’s growth. The Alibaba marketplace is massive and it allows Chinese companies to sell abroad, while at the same time allowing domestic consumers to sell to each other.

Sales Continue To Drive Margins

On mobile devices alone, the company recorded as many as 755 million monthly active users in China. On top of e-commerce, Alibaba has also branched into a tech company. It has its own cloud service known as Alibaba Cloud and has also created its own payments platform Alipay. Alipay already boasts of as many as 600 million users.

Moreover, despite trade tensions with the United States, the Chinese economy is expected to grow over the next decade and expand the size of the middle class. China is already the biggest market for e-commerce companies and the expanding middle class will continue to contribute towards its hyper-growth. Joseph Tsai, the company’s vice chairman stated that even smaller cities in China are expanding rapidly and that retail consumption would hit $7 trillion by 2030.

Last but not least, the company has consistently delivered impressive financial results and in the recent quarters, it has managed to beat analysts’ earnings estimates comfortably.

Continue Reading

Featured

Stock Price Newsletter – September 23, 2019

Jon Phillip

Published

on

biotech stock to watch 2019

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

The fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

See For Yourself, CLICK HERE


This Stock is Looking to Disrupt the Multi-Billion Dollar Defense Industry

Global spending on security solutions is projected to reach $7.4 billion in 2019 and increase to over $11.3 billion by 2025 with a CAGR of 8.2% and is forecast to see consistent growth for the next several years. What Could This Mean For ONE COMPANY?

Read More


Multi-Billion Dollar Markets Are Ready For A Shake-Up

There’s no denying that biotechnology is one of the hottest markets in the world. Right now a multi-billion-dollar segment is ready for a shakeup and one biotech stock could hold the secret to doing just that!

Continue Reading

Continue Reading

Biotechnology

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

Joe Samuel

Published

on

stock market today

Biotech has been one of the hottest sectors for investors for as long as it has existed and the reasons are self-evident. It is a sector that uses cutting edge technology and comes up with treatments for a wide range of diseases.

Moreover, the fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 19, PharmaCyte saw more than 6 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

What To Watch For

This week PharmaCyte (PMCB) will host a call designed to update all shareholders and the investment community simultaneously of material developments. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. FDA to treat locally advanced, inoperable pancreatic cancer. It will also cover developments related to PharmaCyte’s product pipeline. PharmaCyte has been working on these and will discuss things not yet reported in a press release.

Catalyst Pharmaceuticals (CPRX)

The first one to watch is Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). It is a small-cap stock engaged in developing medicines for rare diseases. Catalyst managed to get an approval for one of its products from the FDA earlier this year.

Since the approval of the Lambert-Eaton myasthenic syndrome (LEMS treating medicine Firdapse, Catalyst stock went on a massive rally from January to April. The approval of a rival drug halted the rally. Only after a civil suit from Catalyst did the stock stabilize somewhat.

Last week, Catalyst stock received a fresh boost after the company announced that it was going to make a secondary offering. However, the company decided to pull the offering the very next day and that affected the stock price once again.

What To Watch For

Analysts believe that pulling the secondary offering was the right long term decisions and this stock could be heading for another rally soon.

Eyepoint Pharmaceuticals (EYPT)

The biotech stock that could prove to be a major winner in the biotech sector this month is that of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT). There are two factors at play. The company revenues are going to rise significantly in the coming years due to the commercial launch of two medicines.

The first one is Yutiq, which is meant for the treatment of chronic non-infectious uveitis and the other one is Dexycu, which is meant for postoperative ocular inflammation.

What To Watch For

The company is currently trading at only double that of its future revenue and that is a very attractive multiple. EYPT stock has caught the attention of analysts on Wall Street. Guggenheim has set a 12-month target price of $4, which reflects 116% gains during the period.

stock market news today
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com